Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

4(66.7%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 4(4)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00176306Phase 4Completed

Levofloxacin Pharmacokinetics (PK) in the Severely Obese

Role: collaborator

NCT00211744Phase 4Completed

Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder

Role: collaborator

NCT00187928Phase 3Completed

Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder

Role: collaborator

NCT00439972Phase 2Unknown

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

Role: collaborator

NCT00200941Phase 4Completed

Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome

Role: collaborator

NCT00239161Phase 4Terminated

Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin

Role: collaborator

All 6 trials loaded